23 May 2013
Keywords: bayer, lipobay, cleared, uk, its, first, market
Article | 10 March 1997
Bayer AG has been granted approval in the UK to market its HMG-CoAreductase inhibitor Lipobay (cerivastatin) for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 March 1997
3 March 1997
10 March 1997
© 2013 thepharmaletter.com